Immunovant, Inc.
IMVT
$25.75
$0.110.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -21.29% | -43.86% | -64.12% | -59.58% | -57.20% |
| Total Depreciation and Amortization | 27.11% | 44.33% | 56.59% | 63.20% | 50.23% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 17.81% | 18.46% | 21.98% | 17.45% | 19.16% |
| Change in Net Operating Assets | -261.21% | -600.87% | -59.57% | -557.10% | 232.58% |
| Cash from Operations | -30.15% | -58.65% | -71.60% | -75.46% | -54.50% |
| Capital Expenditure | 71.61% | 42.19% | -16.10% | -110.83% | -200.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 71.61% | 42.19% | -16.10% | -110.83% | -200.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 19,137.47% | 0.44% | -4.43% | -4.94% | -98.86% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 94.69% | 94.69% | 94.69% | 100.00% |
| Cash from Financing | 19,120.79% | 1.65% | -3.28% | -3.80% | -98.85% |
| Foreign Exchange rate Adjustments | -94.93% | -112.95% | -111.20% | -24.77% | 277.97% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 296.00% | -75.90% | -83.09% | -69.63% | -222.42% |